Core Viewpoint - The U.S. dollar is facing significant challenges that may lead to a "controlled decline" in its dominance as the primary global reserve currency by 2026, influenced by structural headwinds such as fiscal deficits and the rise of digital assets [1][2]. Group 1: Dollar's Global Position - The dollar's share of global reserves has decreased from 72% in 1999 to approximately 57% today, indicating a potential shift in its status [2]. - Analysts suggest that the dollar's era of effortless strength may be over, with concerns about its safe-haven status due to fiscal imbalances [2]. - Predictions indicate that the dollar may be lower in value by 2026, with estimates of a 20-30% decline over the next five years [2]. Group 2: Market Sentiment and Forecasts - J.P. Morgan holds a "net bearish" outlook for the dollar in 2026, citing a Federal Reserve focused on labor market softness [3]. - Morgan Stanley presents a contrasting view, forecasting a potential drop in the dollar index to 94 in Q2 2026, followed by a recovery to 100 by year-end [3][4]. - J.P. Morgan anticipates the Euro could rise to 1.20 by December 2026, supported by Eurozone growth and fiscal expansion [4]. Group 3: Digital Assets as a Threat - The emergence of digital assets, particularly stablecoins, poses a new structural threat to the dollar's dominance, with the GENIUS Act expected to establish a regulatory framework for stablecoins by 2025 [5]. - Stablecoins are seen as a significant upgrade in how money moves, offering faster and more transparent alternatives to traditional systems [5]. - The shift towards "on-chain" capital formation is projected to reach $100 trillion in five years, indicating a diversification away from traditional banking [6]. Group 4: Current Dollar Index Performance - As of the article's publication, the U.S. Dollar Index was down 0.05% at 97.9840, reflecting a year-to-date decline of 9.70% but a 1.29% increase over the last six months [6]. - Various ETFs tracking the dollar index have shown mixed performance, with some funds experiencing significant declines [7][8].

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as an affordable stock with promising earnings growth potential for 2026 [1] - The FDA approved RYBREVANT FASPRO, a subcutaneously administered targeted therapy for patients with EGFR-mutated non-small cell lung cancer, co-formulated with ENHANZE® [1] - RYBREVANT FASPRO significantly reduces administration time from several hours to approximately five minutes and decreases administration-related reactions by about fivefold [2] Company Developments - Halozyme's RYBREVANT FASPRO is the first and only subcutaneous therapy for EGFR+ mNSCLC, enhancing patient convenience and speed of administration [1][2] - The company utilizes advanced auto-injector technology to develop drug-device combination products, focusing on patient comfort and adherence [4] Market Ratings - TD Cowen reaffirmed a Buy rating for Halozyme with a price target of $79, while Goldman Sachs downgraded the stock to Sell with a price target of $56 [3] - Goldman Sachs highlighted concerns regarding the long-term value of Halozyme's Enhanze royalty model, predicting a significant revenue decline post-2030 [3]

Group 1 - TD Cowen has lowered the target price for DigitalBridge from $20 to $16, indicating a shift in market sentiment towards the company [1] - The rating for DigitalBridge has been downgraded from "Buy" to "Hold" by TD Cowen, reflecting a more cautious outlook [1] - This downgrade follows SoftBank's announcement of a $4 billion acquisition of DigitalBridge, which may impact investor confidence and market dynamics [1]

for more on the metals trade. Daniel Galley, TD Cowan, commodity strategy uh director. And and Daniel, can you tell me for sure that there's uh that there's nothing uh technical or or short covering or nothing like that going on with silver.All the conspiracy theorists think that I mean, it reminds me I saw $50 silver 30 whenever it was. I I I can't even do the math. I'm so old.But uh you know during the Hunt Brothers what was that 19 when was that 1980 or something. >> 25 years. >> Yeah. Yeah.Exactly. >> A ...

Group 1 - Tonix Pharmaceuticals (TNXP) has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share [1] - In addition to common stock, the agreement includes pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant [1] - The gross proceeds of the offering are expected to be approximately $20 million before deducting placement agent fees and other estimated offering expenses [1] Group 2 - The closing of the offering is anticipated to occur on or about December 30, subject to customary closing conditions [1] - TD Cowen is acting as the sole placement agent for the offering, while A.G.P./Alliance Global Partners is serving as a financial advisor [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SLM Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's financial health and delinquency rates [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in SLM between July 25, 2025, and August 14, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against SLM, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Allegations Against SLM - The complaint alleges that SLM and its executives made false and misleading statements regarding the company's financial stability, particularly concerning early-stage delinquencies and the effectiveness of loss mitigation programs [4]. - A report from TD Cowen indicated that July 2025 delinquencies increased by 49 basis points month-over-month, contradicting SLM's previous assurances about delinquency rates following normal seasonal trends [5]. Group 3: Market Impact - Following the TD Cowen report, SLM's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 per share on August 15, 2025 [5].

"比特币大户"Strategy(MSTR.US)在过去一周将其现金储备提高至21.9亿美元，并暂停了比特币的购买。这家全球最大的数字资产储备公司似乎正在为一场漫 长的加密货币寒冬做准备。根据周一向美国证券交易委员会(SEC)提交的一份文件，Strategy在截至12月21日的七天内通过出售普通股筹集了7.48亿美元。此 前两周内，该公司已购买了约20亿美元的比特币，使其比特币总持仓规模达到约600亿美元。 值得一提的是，指数编制公司MSCI正考虑将持有比特币或其他数字资产作为库藏资产的公司排除在其指数之外，并已就此事征求投资界意见。MSCI表 示："MSCI提议，将数字资产持仓占总资产50%及以上的公司，从MSCI全球可投资市场指数系列中剔除。"此次意见征询期将持续至12月31日，最终决定将 于2026年1月15日前公布。 这意味着Strategy可能会面临被MSCI等主流指数剔除的风险。目前，Strategy是纳斯达克100指数、MSCI美国指数及MSCI全球指数的成分股。摩根大通分析 师在11月发布的报告中指出，在Strategy的总市值中，约90亿美元可能通过与主要基准指数挂钩的交易所交易基金(ETF) ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of SLM Corporation a/k/a Sallie Mae ("SLM†or the "Company†) (NASDAQ: SLM) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SLM CORPORATION (SLM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 14, 2025, investment bank TD Cowen issued a report s. ...

RT Yogita Khatri (@Yogita_Khatri5).@saylor’s @Strategy can withstand even a “prolonged crypto winter,” TD Cowen says.Strategy today said it has boosted its USD reserve to $2.19 billion, a move TD said improves liquidity and financial flexibility even if bitcoin volatility persists.“Concerns around the viability of Strategy’s balance sheet are overblown, in our opinion,” TD wrote.The firm reiterated its buy rating, maintaining a $500 price target over the next 12 months. ...

Strategy is positioned for a 'prolonged crypto winter' after boosting cash reserve, TD Cowen says https://t.co/ggTKGr2jt6 ...